Trials / Completed
CompletedNCT05987371
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.
Randomized, Double-blind, Placebo-controlled, Dose Exploration, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 30 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II clinical trial to evaluate the efficacy and safety of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQC3721 suspension for inhalation | TQC3721 suspension for inhalation is a dual inhibitor targeting PDE3/4. |
| DRUG | TQC3721 matching placebo for inhalation | Placebo without active substance. |
| DRUG | Salbutamol sulfate inhalation aerosol | Salbutamol is short-acting β2 receptor agonists. |
Timeline
- Start date
- 2023-08-23
- Primary completion
- 2024-01-16
- Completion
- 2024-04-23
- First posted
- 2023-08-14
- Last updated
- 2025-04-17
Locations
11 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05987371. Inclusion in this directory is not an endorsement.